In the second National Health and Nutrition Examination Survey (NHANES II), there was a 27% nonresponse rate in the examination phase. This report investigates the potential bias in these data due to this large nonresponse rate. Data from a household and medical history interview are used in the investigation of factors related to examination status. In addition, data from the examined group are compared to data from the 1976 National Health Interview Survey (NHIS). Since there was only a 3.7% nonresponse rate for the 1976 NHIS, proportions calculated from these data represent reasonable estimates of the true population values. Several variables have a significant association with the interview and examination status. However, it appears that the nonresponse and poststratification adjustments performed by the National Center for Health Statistics have removed most of these factors as sources of bias. There is excellent agreement in the marginal distribution of variables between NHANES II for examined persons and the 1976 NHIS.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/oxfordjournals.aje.a113568 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Background: Identifying strategies to engage with potential participants is critical for efficient enrollment in Alzheimer's Disease (AD) trials. Previous studies link faster speed of first contact with successful phone interview completion for Major Depressive Disorder (MDD) participants. This has not been examined in AD participants.
View Article and Find Full Text PDFDevelopment and validation of a nomogram to predict survival after neoadjuvant chemotherapy in elderly women with triple-negative invasive ductal breast cancer: A SEER population-based study.
Saudi Med J
January 2025
From the Department of Breast and Thyroid Surgery (Y. Gao, J. Wang, S. Wang, Tao, Duan, Hao, M. Gao), Tianjin Union Medical Center, from the Department of Thyroid and Neck Oncology (Y. Gao), Tianjin Medical University Cancer Hospital, National Clinical Research Center for Malignant Tumors, Tianjin Clinical Research Center for Malignant Tumors, Tianjin Key Laboratory of Cancer Prevention and Treatment, and from the Medical College (J. Wang, S. Wang), Nankai University, Tianjin, China.
Objectives: To construct and verify a nomogram for post-neoadjuvant chemotherapy survival predication in elderly women with triple-negative invasive ductal breast cancer.
Methods: Elderly patients diagnosed as triple-negative invasive ductal breast cancer between 2019-2000 were screened from surveillance, epidemiology, and end results database. Depending on the post-neoadjuvant chemotherapy pathological response, they were assigned to the complete or non-complete response group.
Background: The armamentarium of medical therapies to treat inflammatory bowel disease (IBD) continues to grow, which has expanded treatment options, particularly after first biologic failure. Currently, there are limited studies investigating the predictive value of first biologic primary non-response (PNR) on subsequent biologic success. Our objective was to determine if PNR to the first biologic for IBD is predictive of response to subsequent biologic therapy.
View Article and Find Full Text PDFTreatment Persistence Among Anti-Tumor Necrosis Factor-experienced Patients With Ulcerative Colitis Switching to a Biologic With a Different Mode of Action or Cycling to Another Anti-Tumor Necrosis Factor Agent.
Clin Ther
December 2024
Analysis Group, Inc, Montreal, Quebec, Canada.
Purpose: In ulcerative colitis (UC), anti-tumor necrosis factor (TNF) agents often are first-line biologic therapy. Switching to a biologic with a different mode of action (ustekinumab and vedolizumab) or cycling to another anti-TNF agent (adalimumab, infliximab, and golimumab) is necessary if an initial anti-TNF fails. This study compared real-world persistence in patients with UC who switched to a biologic with a different mode of action or cycled with another anti-TNF after nonresponse to an anti-TNF.
View Article and Find Full Text PDFComputed Tomography Scan and Clinical-based Complete Response Prediction in Locally Advanced Rectal Cancer after Neoadjuvant Chemoradiotherapy: A Machine Learning Approach.
J Med Signals Sens
December 2024
Radiation Biology Research Center, Iran University of Medical Sciences, Tehran, Iran.
Background: Treatment of locally advanced rectal cancer (LARC) involves neoadjuvant chemoradiotherapy (nCRT), followed by total mesorectal excision. Examining the response to treatment is one of the most important factors in the follow-up of patients; therefore, in this study, radiomics patterns derived from pretreatment computed tomography images in rectal cancer and its relationship with treatment response measurement criteria have been investigated.
Methods: Fifty patients with rectal adenocarcinoma who were candidates for nCRT and surgery were included.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!